Year archive

Xspray Pharma — 2022 filings

All 31 regulatory filings released by Xspray Pharma (XSPRAY) in 2022, sourced directly from the official regulator.

31 Filings

2022 Period

2022 filings (31)

Filing	Released	Lang
Interim / Quarterly Report 2022 Interim / Quarterly Report Q3 2022	2022-11-09	Swedish
Interim / Quarterly Report 2022 Interim / Quarterly Report Q3 2022	2022-11-09	English
Major Shareholding Notification 2022 Major Shareholding Notification	2022-10-31	English
Number of shares and votes in Xspray Pharma Declaration of Voting Results & Voting Rights Announcements	2022-10-31	English
Antal aktier och röster i Xspray Pharma Declaration of Voting Results & Voting Rights Announcements	2022-10-31	Swedish
Xspray Pharmas valberedning inför årsstämman 2023 Board/Management Information	2022-10-25	Swedish
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2023 Board/Management Information	2022-10-25	English
Xspray Pharma har genomfört en riktad emission som tillför bolaget 100 MSEK Share Issue/Capital Change	2022-10-17	Swedish
Xspray Pharma has carried out a directed share issue raising proceeds of MSEK 100 Share Issue/Capital Change	2022-10-17	English
Interim / Quarterly Report 2022 Interim / Quarterly Report Q2 2022	2022-08-05	Swedish
Interim / Quarterly Report 2022 Interim / Quarterly Report Q2 2022	2022-08-05	English
Dasynoc har beviljats särläkemedelsstatus i USA för behandlingen av kronisk myeloisk leukemi Regulatory Filings	2022-06-17	Swedish
Dasynoc granted Orphan Drug Designation in the US for the treatment of chronic myeloid leukemia Regulatory Filings	2022-06-17	English
Thomas Walz blir Chief Medical Officer på Xspray Pharma Board/Management Information	2022-06-15	Swedish
Xspray Pharma appoints Thomas Walz as Chief Medical Officer Board/Management Information	2022-06-15	English
Kommuniké från Årsstämma 2022 i Xspray Pharma AB (publ) AGM Information	2022-05-19	Swedish
Bulletin from the 2022 Annual General Meeting of Xspray Pharma AB (publ) AGM Information	2022-05-19	English
Interim / Quarterly Report 2022 Interim / Quarterly Report Q1 2022	2022-05-06	Swedish
Interim / Quarterly Report 2022 Interim / Quarterly Report Q1 2022	2022-05-06	English
Major Shareholding Notification 2022 Major Shareholding Notification	2022-04-25	English
Kallelse till årsstämma i Xspray Pharma AB (publ) AGM Information	2022-04-19	Swedish
Notice of annual general meeting of Xspray Pharma AB (publ) AGM Information	2022-04-19	English
Major Shareholding Notification 2022 Major Shareholding Notification	2022-04-11	English
Annual Report (ESEF) 2021 Annual Report (ESEF) FY 2021	2022-03-25	Swedish
Annual Report (ESEF) 2021 Annual Report (ESEF) FY 2021	2022-03-25	Swedish
Earnings Release 2021 Earnings Release FY 2021	2022-02-18	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report FY 2021	2022-02-18	English
Xspray Pharma appoints Global Head of Marketing and Sales Board/Management Information	2022-02-07	English
Xspray Pharma tillsätter Global Kommersiell Chef Board/Management Information	2022-02-07	Swedish
FDA allows review of application for market approval for Xspray Pharma’s Dasynoc™ Regulatory Filings	2022-01-13	English
FDA godkänner att pröva ansökan om marknadsgodkännande för Xspray Pharmas Dasynoc™ Regulatory Filings	2022-01-13	Swedish